Bristol Myers Squibb Announces the Committee for Medicinal Products for Human Use (CHMP) has Recommended the Approval of Sotyktu (Deucravacitinib) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

Bristol Myers Squibb (BMS) announced the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for once-daily Sotyktu (deucravacitinib) as a treatment for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. The CHMP decision was based on results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 trials and an additional two years of data from the POETYK PSO long-term extension trial. The CHMP recommendation will be reviewed by the European Commission, and if approved, Sotyktu would be the first oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor in the European Union for the treatment of any disease.